Skip to main content
Clinical Trials/NCT07313072
NCT07313072
Not yet recruiting
Phase 2

Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study

Hexsel Dermatology Clinic0 sites10 target enrollmentStarted: March 1, 2026Last updated:

Overview

Phase
Phase 2
Status
Not yet recruiting
Sponsor
Hexsel Dermatology Clinic
Enrollment
10
Primary Endpoint
The efficacy of topical 2% tofacitinib

Overview

Brief Summary

To evaluate the efficacy and safety of topical 2% tofacitinib nail lacquer in nail psoriasis, using the NAPSI and DLQI scales before and after 26 weeks of treatment.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥ 18 years;
  • Presence of nail psoriasis in at least one fingernail or toenail;
  • Patients not using systemic medication, or without adequate response to systemic medication after at least 6 months of use;
  • Ability to read, understand, and sign the Informed Consent Form (ICF) and the Consent Form for Images, Presentations, and Scientific Publications.

Exclusion Criteria

  • Pregnant or breastfeeding women or those planning to become pregnant during the study period;
  • History of sensitivity to any components of the study product;
  • Initiation of systemic medication for nail psoriasis less than six months prior.

Arms & Interventions

Medicated Nail Lacquer

Experimental

Intervention: Topical 2% Tofacitinib (Drug)

Outcomes

Primary Outcomes

The efficacy of topical 2% tofacitinib

Time Frame: 26 weeks

The Nail Psoriasis Severity Index (NAPSI) evaluates nail psoriasis severity by assessing a target nail for nail matrix and nail bed involvement. The nail is divided into four quadrants. Nail matrix psoriasis includes pitting, leukonychia, red spots in the lunula, and nail plate crumbling, while nail bed psoriasis comprises onycholysis, splinter hemorrhages, oil drop (salmon patch) discoloration, and nail bed hyperkeratosis. Each component is scored from 0 to 4 according to the number of quadrants affected (1 = 1/4, 2 = 2/4, 3 = 3/4, 4 = 4/4). The total NAPSI score per nail is calculated as the sum of matrix and nail bed scores, ranging from 0 to 8. The score is directly proportional to disease severity, with higher scores indicating greater nail involvement and a score of zero representing absence of nail manifestations. In clinical studies, a decrease in NAPSI score over time indicates clinical improvement.

Secondary Outcomes

  • Safety, Quality of Life, and Treatment Adherence with 2% Tofacitinib(26 weeks)

Investigators

Sponsor
Hexsel Dermatology Clinic
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Doris Hexsel

Dr

Hexsel Dermatology Clinic

Similar Trials